- Iclaprim as a fixed-dose 2-hour infusion outperforms weight-based dosing for efficacy and safety in patients with acute bacterial skin and skin structure infections (ABSSSIs).
Why this matters
- This dihydrofolate reductase inhibitor is being used in a "broad range" of patients with ABSSSI or Gram-positive complicated skin and skin structure infections (cSSSIs), along with older age and comorbidities such as diabetes, according to results presented at ASM Microbe 2019.
- Iclaprim in fixed-dose via 2-hour infusion showed improved minimum inhibitory concentration values that improved by 54% and 67% over values for the weight-based, 30-minute dose.
- Maximum concentration values also improved, decreasing by 7.3%.
- Data are from phase 3 REVIVE 1 and 2 studies of the fixed-dose regimen vs vancomycin compared with results from ASSIST 1 and 2 studies of the weight-based dose vs linezolid.
- These data were presented without peer review at a conference.